{
    "clinical_study": {
        "@rank": "42136", 
        "arm_group": {
            "arm_group_label": "Deoxycoformycin (DCF)/Pentostatin", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the side effects and antitumor response of\n      patients with lymphoid malignancies to Deoxycoformycin (DCF)/Pentostatin."
        }, 
        "brief_title": "A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies", 
        "completion_date": {
            "#text": "November 2006", 
            "@type": "Actual"
        }, 
        "condition": [
            "Peripheral T-cell Lymphoma", 
            "Cutaneous T-cell Lymphoma", 
            "Chronic Lymphocytic Leukemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Lymphocytic, Chronic, B-Cell", 
                "Leukemia, Lymphoid", 
                "Lymphoma", 
                "Lymphoma, T-Cell", 
                "Lymphoma, T-Cell, Cutaneous", 
                "Lymphoma, T-Cell, Peripheral"
            ]
        }, 
        "detailed_description": {
            "textblock": "Deoxycoformycin(DCF)/Pentostatin is a T-cell cytotoxic drug with previously reported\n      responses in lymphoid malignancies but larger studies are needed."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologic proof of lymphoid malignancy with an expected complete response rate of\n             less than 20 percent OR have failed at least one prior therapy.\n\n          -  No chemotherapy within 3 weeks of entry into study and must have recovered from acute\n             toxic effects of prior therapy.\n\n          -  Life expectancy of at least 12 weeks.\n\n          -  Performance status equal to or less than Zubrod 2.\n\n          -  Signed informed consent.\n\n          -  Patients with measurable disease.\n\n          -  Age at least 16 years.\n\n          -  Adequate bone marrow function (unless involvement of bone marrow by lymphoma) defined\n             as AGC greater than 1500 and platelet count greater than 100,000.\n\n          -  Adequate hepatic function with a bilirubin less than or equal to 1.5 mg % and SGPT\n             less than or equal to 4 times the upper limits of normal.\n\n          -  Adequate renal function defined as serum creatine less than or equal to 1.5 mg %.\n\n        Exclusion Criteria:\n\n          -  No serious intercurrent illness.\n\n          -  Adequate contraception (if applicable).\n\n          -  NO patients with significant cardiac disease, i.e. New York Heart Association (NYHA)\n             class III or IV.\n\n          -  NO experimental clinical trial within 3 weeks of study entry.\n\n          -  NO patients with active CNS disease.\n\n          -  Full recovery from any prior surgical treatment.\n\n          -  NO active active infections."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "16 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 24, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00038025", 
            "org_study_id": "DM94-026"
        }, 
        "intervention": {
            "arm_group_label": "Deoxycoformycin (DCF)/Pentostatin", 
            "description": "Patients received Deoxycoformycin (DCF)/Pentostatin administered by intravenous bolus daily over a consecutive 3-day period. This course was repeated at 3-week intervals.", 
            "intervention_name": "Deoxycoformycin (DCF)", 
            "intervention_type": "Drug", 
            "other_name": [
                "Nipent", 
                "Pentostatin"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Pentostatin", 
                "Adenosine Deaminase Inhibitors"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Mycosis Fungoides", 
            "Lymphoma", 
            "Chronic lymphocytic leukemia", 
            "Deoxycoformycin", 
            "Pentostatin", 
            "All other lymphomas", 
            "Nucleoside analogue", 
            "Adenosine deaminase inhibitor", 
            "T-cells"
        ], 
        "lastchanged_date": "August 1, 2012", 
        "link": {
            "description": "Public website for M. D. Anderson Cancer Center", 
            "url": "http://www.mdanderson.org"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Houston", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "77030"
                }, 
                "name": "M. D. Anderson Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Study of Deoxycoformycin (DCF) in Lymphoid Malignancies", 
        "overall_official": {
            "affiliation": "MD Anderson", 
            "last_name": "Razelle Kurzrock, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2006", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Overall responses (OR) of participants with lymphoid malignancies to Deoxycoformycin (DCF)/Pentostatin defined as Complete Response (CR) and Partial Response (PR).", 
            "measure": "Number of Participants with Overall Response", 
            "safety_issue": "No", 
            "time_frame": "Baseline and approximately every 3 weeks thereafter"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00038025"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "M.D. Anderson Cancer Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "M.D. Anderson Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 1994", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }, 
    "geocoordinates": {
        "M. D. Anderson Cancer Center": "29.76 -95.369"
    }
}